Quinoline and Quinazoline Alkaloids against COVID-19: An In Silico Multitarget Approach

The recent outbreak of the highly contagious coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 has created a global health crisis with socioeconomic impacts. Although, recently, vaccines have been approved for the prevention of COVID-19, there is still an urgent need for...

Full description

Saved in:
Bibliographic Details
Main Authors: Esraa M. O. A. Ismail, Shaza W. Shantier, Mona S. Mohammed, Hassan H. Musa, Wadah Osman, Ramzi A. Mothana
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Journal of Chemistry
Online Access:http://dx.doi.org/10.1155/2021/3613268
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recent outbreak of the highly contagious coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 has created a global health crisis with socioeconomic impacts. Although, recently, vaccines have been approved for the prevention of COVID-19, there is still an urgent need for the discovery of more efficacious and safer drugs especially from natural sources. In this study, a number of quinoline and quinazoline alkaloids with antiviral and/or antimalarial activity were virtually screened against three potential targets for the development of drugs against COVID-19. Among seventy-one tested compounds, twenty-three were selected for molecular docking based on their pharmacokinetic and toxicity profiles. The results identified a number of potential inhibitors. Three of them, namely, norquinadoline A, deoxytryptoquivaline, and deoxynortryptoquivaline, showed strong binding to the three targets, SARS-CoV-2 main protease, spike glycoprotein, and human angiotensin-converting enzyme 2. These alkaloids therefore have promise for being further investigated as possible multitarget drugs against COVID-19.
ISSN:2090-9063
2090-9071